Pitocina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pitocina

Property Description
Active ingredient Oxytocin
Form Sterile aqueous solution for injection
Pharmacological class Oxytocic Agent, Uterotonic Agent
Common purpose Management of uterine contractions
Origin Synthetic nonapeptide hormone

What is Pitocina and What Class of Medicine Does It Belong To?

Pitocina is the brand name for a sterile pharmaceutical preparation containing the active ingredient Oxytocin, the International Nonproprietary Name (INN) for this compound. It is officially classified as an Oxytocic Agent, a class of medicine that specifically influences the muscular activity of the uterus. This definition places Pitocina within the neurohypophyseal hormone group, identifying it as a potent and targeted medication, and it is clinically recognized as a powerful uterotonic agent.


Is Pitocina a Natural Hormone or a Synthetic Preparation?

Pitocina is a synthetic preparation of the naturally occurring nonapeptide hormone Oxytocin. It is a single-ingredient product, chemically engineered to be molecularly identical to the hormone produced by the body, but manufactured in a laboratory setting to ensure purity and consistency. It is formulated as a sterile, clear, colorless aqueous solution designed specifically for administration via intravenous infusion or intramuscular injection. The synthetic origin ensures a standardized, precisely measurable dosage, which is critical for safety and clinical precision.


What is the General Purpose of an Oxytocic Agent?

The general purpose of an oxytocic agent like Pitocina is to selectively bind to receptors in the uterine muscle (myometrium) to generate or enhance contractions. By acting as an Oxytocin receptor agonist, the medication provides a controlled stimulus to the uterus. This uterotonic action is essential for managing the muscular forces of the uterus, for instance, securing firm contraction after delivery to effectively control blood loss by compressing internal blood vessels.

Regulatory References

  1. Oxytocin Injection: MedlinePlus Drug Information

What side effects are possible with Pitocina?

Possible Side Effects and Safety Information

The safety profile of Pitocina (Oxytocin) is officially documented by government regulatory agencies, detailing potential adverse reactions and special safety considerations. The occurrence of side effects is often dose-related, meaning risk may increase with higher exposure.


Documented Adverse Reactions by Frequency

Adverse effects are categorized based on their expected frequency in regulatory labeling.

Classification Examples (Maternal)
Common Headache, Nausea, Vomiting, Tachycardia, Bradycardia
Rare Anaphylactic reaction/shock
Frequency Not Known Uterine rupture, Disseminated Intravascular Coagulation (DIC), Severe Water Intoxication, Acute Pulmonary Edema, Fetal Death

Serious Reactions and System-Organ Classes

The label identifies several serious adverse reactions including Uterine Rupture and Fatal Afibrinogenemia (a severe clotting disorder). Adverse effects are grouped by the body system affected, officially known as System-Organ Classes. Key affected systems include the Pregnancy, Puerperium, and Perinatal conditions, Blood and Lymphatic System, and Cardiac Disorders (e.g., Myocardial Ischemia, QTc prolongation).


Safety Considerations and Restrictions

Official labeling contains specific constraints and warnings:

  • Administration Restriction: Pitocina must never be administered by intravenous bolus injection, as this may cause acute hypotension.
  • Exposure Pattern: Risk of Water Intoxication is noted when high doses are given for prolonged periods with large volumes of electrolyte-free fluid.
  • Specific Populations: Caution is required for patients with pre-existing Cardiovascular Disease or Severe Renal Impairment. Women over 35 years of age or with a gestational age over 40 weeks have a documented increased risk for postpartum DIC.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Pitocina (Oxytocin) is officially documented in regulatory labeling to lead to two primary, severe physiological effects: uterine hyperactivity and water intoxication. The official guidance strictly addresses the resulting severe outcomes and the necessary emergency actions.

Documented Manifestations and Severe Outcomes

Manifestation Type Officially Documented Outcomes
Uterine Hyperactivity Severe hyperstimulation may cause tumultuous labor, uterine rupture, cervical and vaginal lacerations, and acute postpartum hemorrhage. Fetal distress, indicated by variable deceleration of the fetal heart rate, may also occur, potentially leading to fetal death.
Systemic Toxicity The antidiuretic effect may cause water intoxication, particularly with high-dose, long-duration infusions. Manifestations may progress to convulsions, coma, and are documented as a potential cause of maternal death.

Required Emergency Response

When signs of overdosage, such as uterine hyperstimulation or fetal distress, are noted, the regulatory documents strictly require the immediate discontinuation of oxytocin administration. Immediate medical help must be sought if any of these severe manifestations occur. Management consists of symptomatic and supportive therapy, as no specific antidote is known. Procedures may include administering oxygen to the mother and positioning her laterally.

Therapeutic Uses of Pitocina

What Pitocina Treats: Main Uses and Benefits

Pitocin (synthetic oxytocin) plays a role in managing symptoms related to heightened physiological activity specifically concerning uterine contractility. The medicine is commonly used in both antepartum (before delivery) and postpartum (after delivery) situations for therapeutic assistance.

Therapeutic Domains and Symptom Management

The core therapeutic domains involve conditions presenting with acute episodes where assistance with stimulating contractions is required. This is relevant for situations that may involve labor induction or augmentation (strengthening) of contractions due to inefficiency, as well as addressing excessive bleeding (hemorrhage) after delivery. Pitocin is applied in clinical settings that involve acute or unstable symptom patterns, supporting relief by helping ease the overall symptom burden.

Supportive Relief

Pitocin is commonly used when short-term symptomatic assistance is needed to begin the birthing process or manage post-delivery complications. It helps address symptom clusters that may become disruptive, offering symptomatic relief that helps patients cope more steadily with difficult episodes. It is also relevant for helping manage postpartum bleeding, where the medication provides support to address potential excessive blood loss, thereby helping ease the overall symptom burden.


Quick Fact: Relevant for Managing Physiological Strain

Pitocin is applied across domains where additional symptomatic support is needed in conditions characterized by periods of heightened symptoms related to uterine function.

Eligibility and Restrictions for Use

Eligibility Profile: Pitocina (Oxytocin Injection)

This section outlines the eligibility criteria and contraindications for Pitocina as defined by official regulatory documents.

Absolute Contraindications

Pitocina is contraindicated and must not be used in individuals with hypersensitivity to oxytocin or any excipients. It is also prohibited in patients with conditions where vaginal delivery is unsafe, including total placenta previa, vasa previa, cord presentation or prolapse, invasive cervical carcinoma, or active herpes genitalis. The medicine is also excluded in cases of significant cephalopelvic disproportion or when the uterus is already hyperactive or hypertonic.

Restricted and Conditional Use

Use is restricted or requires extreme caution in several groups due to increased risk of complications. This includes patients with a history of previous major surgery on the uterus or cervix (such as prior Caesarean section) and individuals with grand multiparity. Caution is also required for patients with pre-existing cardiovascular disease or renal impairment.

Populations with Limited Data

Elective induction of labor is not indicated due to insufficient data to evaluate the benefits against the risks. Furthermore, safety and efficacy are not established for use in the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe specific and significant interactions with certain medicinal products and classes that necessitate careful management or avoidance during use.

Documented Interaction Domains

Interacting Product Category Nature of Interaction Required Management/Constraint
Prostaglandins (used for labor induction) Additive Uterotonic Effect: Increased sensitivity of the uterus. Concurrent use is restricted; sequential use requires a specified time interval (e.g., discontinuation for a period before starting oxytocin infusion) to avoid uterine hyperstimulation, rupture, and fetal distress.
Vasoconstrictors and Pressor Agents (especially with caudal block anesthesia) Enhanced Pressor Effect: Risk of severe, persistent hypertension. Intensive Monitoring Required: Blood pressure must be monitored closely when oxytocin is administered following or with these agents in this specific anesthetic context.
Inhalational Anesthetic Agents (e.g., Halothane) Clinical Effect Modification: Weakening of oxytocin's uterine contractions; potential for arrhythmias. Use may require dose adjustment or alternative management to ensure therapeutic efficacy and monitor cardiac rhythm.

Official Constraints and Context

The primary constraints defined by official labeling relate to managing the risk of uterine hyperstimulation when used with other uterotonic agents like prostaglandins, and the risk of severe hypertension when used with vasoconstrictors in the context of regional anesthesia. These interactions are context-dependent, applying specifically to the obstetrical setting where Pitocina (Oxytocin) is utilized for the induction or augmentation of labor. The regulatory basis mandates specific timing and monitoring requirements as a direct result of these documented interactions.

Mechanism of Action

How Pitocina Works

Pitocina (synthetic oxytocin) functions as a selective agonist for the Oxytocin Receptor (OTR), a G-protein coupled receptor highly expressed on uterine smooth muscle (myometrial) cells and myoepithelial cells of the breast. Binding of Pitocina activates the Gq protein pathway, initiating the intracellular signaling cascade. This activation leads to the hydrolysis of PIP2, forming IP3 and triggering the rapid release of intracellular calcium (Ca^2+) from the sarcoplasmic reticulum. The resultant increase in Ca^2+ concentration activates the Myosin Light-Chain Kinase (MLCK) enzyme. MLCK phosphorylates the myosin light chains, thereby engaging the actin-myosin contractile machinery. This process results in the forceful, frequent contraction of uterine smooth muscle and the contraction of myoepithelial cells, leading to milk ejection. The intensity of this mechanism is mediated by high OTR density, which is naturally elevated as the uterus nears term.

Dosage and Administration Information

How Pitocina is Used: Official Administration Guidelines

Pitocina, containing the active ingredient Oxytocin, is administered strictly according to high-level procedural protocols. The method and schedule of administration depend entirely on the specific clinical scenario.


Official Routes and Administration Scope

Property Administration Instruction
Route of Administration Administered by controlled intravenous (IV) infusion for labor management, and as an IV infusion or intramuscular (IM) injection for postpartum hemorrhage control.
Dosing Schedule For Labor Induction/Augmentation: IV infusion starting at 0.5–2 milliunits per minute (mU/min), titrated gradually. For Postpartum Hemorrhage (IM): A single dose of 10 Units administered after placental delivery.

Preparation and Procedural Constraints

For intravenous use, Pitocina must be diluted in an appropriate intravenous solution, such as 0.9% sodium chloride, prior to administration. The infusion must be precisely controlled, often requiring a constant infusion pump, to ensure the accurate low flow rates required for safe and effective use.

Administration for the purpose of labor induction or augmentation must occur in a hospital setting under specialized medical supervision. The dosage is highly individualized based on the patient's uterine response, with the infusion rate increased in small increments (e.g., 1–2 mU/min) at defined intervals (e.g., 30 to 60 minutes) until the desired contraction pattern is established.

Due to its use in acute, supervised settings, Pitocina is not administered according to a standard daily schedule, and instructions for missed doses are not applicable.

Recent Clinical Evidence

Pitocina: Recent Clinical Evidence


Pitocina, a synthetic form of the hormone oxytocin, continues to be an essential medication in modern obstetrics for the induction and augmentation of labor and the prevention and treatment of postpartum hemorrhage (PPH). Recent clinical evidence focuses on optimizing dosing protocols to maximize efficacy while minimizing maternal and fetal risks.

Dosing and Safety in Labor

Clinical guidelines emphasize a cautious, individualized titration of intravenous Pitocina for labor induction or augmentation. The goal is to achieve a contraction pattern similar to normal, spontaneous labor—typically 3 to 4 contractions every 10 minutes.

Research has explored various dosing regimens (low-dose vs. high-dose protocols) and the intervals between dose increases. While some high-dose protocols may potentially shorten the duration of labor, the general consensus and FDA-approved labeling recommend a more conservative, low-dose approach with gradual increases (e.g., 1–2 milliunits/minute) and intervals of 30 to 60 minutes between increases. This conservative approach is associated with a lower risk of uterine hyperstimulation (tachysystole), a condition where contractions are too frequent or prolonged, which can lead to fetal distress.

Comparison with Other Agents

For labor induction in women with an unfavorable cervix, mechanical methods or prostaglandin agents like misoprostol are often used for cervical ripening before Pitocina administration. Studies comparing prostaglandins directly with Pitocina for induction have suggested that prostaglandins may lead to a shorter time to delivery and a lower rate of cesarean delivery for dystocia in certain patient groups, though they may also increase the risk of uterine tachysystole.

Use in Postpartum Hemorrhage

Pitocina remains the first-line uterotonic agent for preventing PPH following vaginal and cesarean delivery. World Health Organization (WHO) recommendations affirm the use of 10 International Units (IU) of oxytocin, administered either intramuscularly or intravenously, for this purpose. Current safety recommendations suggest that intravenous doses be administered slowly (diluted) rather than as a rapid bolus to avoid potential adverse effects such as sudden hypotension.

Frequently Asked Questions (FAQ)

Common questions about Pitocina (FAQ)


Q: How fast does Pitocina start working after it's given?

According to official product information, the onset of action is very quick. Following administration through a vein (intravenous or IV), uterine contractions typically begin within approximately 1 minute. If the medicine is given as a shot into the muscle (intramuscular or IM), contractions usually commence within 3 to 5 minutes.


Q: How long does Pitocina stay in your system after the infusion is stopped?

The medicine's active component, oxytocin, has a very short lifespan in the body. Its half-life (the time it takes for half the drug to be eliminated) is only about 1 to 6 minutes. The short duration is a factor in how the medication is administered and monitored.


Q: What happens if Pitocina is given to someone who is not pregnant?

Official labeling is focused on antepartum (before delivery) and postpartum (after delivery) use. This includes management of incomplete or inevitable abortions (miscarriages) and for specific fetal distress evaluations.


Q: Why do some people say Pitocina makes contractions feel more intense?

Pitocina is used to stimulate or reinforce uterine contractions. The goal is to achieve a consistent contraction pattern, typically 3 to 5 contractions every 10 minutes. By affecting the intensity and frequency of uterine contractions, the medication helps to establish a pattern that progresses labor.


Q: Does using Pitocina increase the need for other interventions?

The primary safety concern with Pitocina is uterine hyperstimulation, where contractions become too frequent or prolonged. If these conditions occur, intervention is necessary. This typically involves reducing or stopping the Pitocina infusion and implementing other care measures.


Q: Is Pitocina only used in late pregnancy or also for other situations?

Pitocina is primarily used for labor induction at or near term, but it has other approved uses. Official product information indicates it is also used as an adjunct in managing incomplete or inevitable abortions (miscarriages).


Q: Can Pitocina be used to help with breastfeeding?

The active ingredient in Pitocina, oxytocin, is molecularly identical to the body's natural hormone that is responsible for the milk ejection or let-down reflex. However, the official uses of Pitocina are limited to labor and delivery management.


Q: What are the signs that a person might be having an allergic reaction to Pitocina?

Severe allergic reactions, including anaphylaxis (a life-threatening reaction) and shock, are rare but possible. Signs that have been reported and should be communicated to the healthcare team include difficulty breathing, dizziness, hives, an itchy skin rash, or swelling of the face, lips, or tongue.


Q: Does Pitocina affect your blood pressure?

Yes, regulatory documents note that Pitocina can affect blood pressure. There is a risk of hypotension (low blood pressure), especially if administered too quickly. The label also notes a risk of severe hypertension when used with certain vasoconstrictor medications.


Q: Can Pitocina be used for non-obstetrical reasons?

The specific indications for Pitocina (Oxytocin Injection) are strictly limited to the antepartum and postpartum periods, such as around the time of birth or miscarriage. Official information focuses on the approved uses.


Q: What is the success rate of inducing labor with Pitocina?

Success rates for labor induction with Pitocina are variable. They depend on many individual factors, such as the stage of pregnancy and the patient’s cervical condition, making care individualized.


Q: Can Pitocina cause water retention or fluid issues?

Yes, oxytocin has known antidiuretic effects, meaning it can cause the body to retain water. High doses given for prolonged periods with large volumes of intravenous fluid are associated with a risk of Severe Water Intoxication. This risk is mitigated by the healthcare team's careful monitoring of fluids and electrolytes during administration.


Q: Is Pitocina commonly used after a twin delivery?

Pitocina is indicated for the prevention and control of postpartum hemorrhage (PPH), which is excessive bleeding after birth. Since the risk of PPH is often higher following multiple births, its use in this context is based on the general PPH indication.


Q: What is the difference between Pitocina and a drug called Syntocinon?

Pitocina and Syntocinon are simply different brand names used across various countries and regions. Both names refer to a sterile preparation of the exact same active pharmaceutical ingredient: Oxytocin.


Q: Does Pitocina make you feel dizzy or lightheaded?

Regulatory-derived information on side effects indicates that feelings of dizziness and lightheadedness are among the possible adverse effects that have been reported.


Q: Can Pitocina be used for a non-live birth or stillbirth?

Official information confirms that Pitocina is indicated for the induction of labor in cases of fetal demise (stillbirth), where it is used to help deliver the fetus.


Q: What are the most common side effects people feel while getting Pitocina?

The most common maternal side effects reported in regulatory labeling include Headache, feelings of Nausea or Vomiting, Tachycardia (a fast heart rate), and Bradycardia (a slow heart rate).


Q: Can Pitocina cause nausea or vomiting?

Yes, Nausea and Vomiting are specifically listed in the official labeling as common adverse effects associated with the use of this medicine.


Q: Does Pitocina affect the baby or just the mother?

Pitocina can affect the baby. Serious fetal adverse effects are usually related to uterine hyperstimulation. These effects include fetal distress, fetal bradycardia (slow heart rate), and, rarely, fetal death, which is why continuous monitoring is performed.


Q: What conditions might make a person unable to receive Pitocina?

Pitocina is contraindicated (should not be used) when there are absolute contraindications related to conditions where vaginal delivery is unsafe. Examples include total placenta previa or when the fetal head is too large for the pelvis (cephalopelvic disproportion).


Q: Can Pitocina be used for a miscarriage or only full-term birth?

Official indications confirm that Pitocina can be used for more than just full-term birth. It is used as an adjunct in the management of an incomplete or inevitable abortion (miscarriage).


Q: Why is the dosage of Pitocina usually started very low?

Dosage is started low and gradually increased (titrated) to achieve a contraction pattern that mimics normal labor. This gradual, low-dose approach is implemented to minimize the risk of uterine hyperstimulation, a condition where contractions are too frequent or prolonged.


Q: Why is Pitocina sometimes used to augment labor that has stalled?

Pitocina is indicated to stimulate or reinforce labor when contractions have become weak or ineffective (uterine inertia). By boosting the intensity and frequency of contractions, it is intended to help re-establish effective labor progression.

How should Pitocina be stored and disposed of?

Storage and Disposal of Pitocin (Oxytocin Injection)

Official regulatory guidelines dictate specific conditions for storing Pitocin (Oxytocin injection) to maintain its integrity. The medication must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is required that the solution be protected from light, and the official labeling advises that freezing is not recommended.

Handling and Protection

The product must be kept in its original container until use. As a standard safety measure for all medications, Pitocin must be stored out of the sight and reach of children.

For disposal, any unused product or waste material must be disposed of in accordance with local requirements and established procedures for pharmaceutical waste, often involving take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pitocina found in:

A-Z Index: